DigestRedComo funciona
Red
/
Empresas
St
No verificado

Stoke Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

52 Comunicados de prensa

Ver todos los comunicados de prensa
04/03/2026
Industria
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Salud
Farmacéutica
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Fuente
Stoke Therapeutics, Inc.
Editor
Business Wire
1.00
0
24/02/2026
Eventos
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Fuente
Stoke Therapeutics, Inc.
Editor
Business Wire
1.00
0
18/02/2026
Mercado de valores
Finanzas
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fuente
Stoke Therapeutics, Inc.
Editor
Business Wire
1.00
0
11/02/2026
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Óptica
Industria
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
Fuente
Stoke Therapeutics, Inc.
Editor
Business Wire
1.00
0
04/02/2026
Biotecnología
Salud
Web y redes sociales
Eventos
Ferias y Congresos
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Fuente
Stoke Therapeutics, Inc.
Editor
Business Wire
1.00
0
16/01/2026
Salud
Biotecnología
Ciencia
Sanidad
Farmacéutica
Mercado de valores
Finanzas
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fuente
Stoke Therapeutics, Inc.
Editor
Business Wire
1.00
0
11/01/2026
Salud
Biotecnología
Medicina - Varios
Ciencia
Farmacéutica
Web y redes sociales
Eventos
Industria
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Fuente
Stoke Therapeutics, Inc.
Editor
Business Wire
1.00
0
06/01/2026
Eventos
Web y redes sociales
Salud
Biotecnología
Medicina - Varios
Ciencia
Farmacéutica
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fuente
Stoke Therapeutics, Inc.
Editor
Business Wire
1.00
0
16/12/2025
Mercado de valores
Finanzas
Ciencia
Biotecnología
Sanidad
Salud
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fuente
Stoke Therapeutics, Inc.
Editor
Business Wire
1.00
0
05/12/2025
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Eventos
Ferias y Congresos
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Fuente
Stoke Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0